Investor Presentaiton
Conclusions
Encouraging antitumor activity was observed with Dato-DXd treatment in a
heavily pretreated NSCLC population with actionable genomic alterations,
including patients with EGFR mutations and ALK rearrangements
Dato-DXd had a manageable safety profile, characterized by a low incidence
of hematologic or drug-related grade ≥3 toxicities. Nausea and stomatitis were
the predominant AEs seen, consistent with previously reported data in NSCLC
The ongoing, randomized, phase 3 TROPION-Lung01 study (NCT04656652) is
assessing Dato-DXd vs docetaxel in patients with pretreated adv/met NSCLC,
including those with actionable genomic alterations
adw/met, advanced/metastatic, AE, adverse event; Dato-DXd, datopotamab deruxtecan; NSCLC, non-small cell lung cancer.
Daiichi-Sankyo
22View entire presentation